CD137 Proteins, Antibodies, cDNA Clones Research Reagents

TNFRSF9 (TNF Receptor Superfamily Member 9) is a protein coding gene located on human chromosome 1p36.23. TNFRSF9 is also known as ILA, 4-1BB, CD137 and CDw137. The human TNFRSF9 gene encodes a 27899 Da protein containing 255 amino acids. The TNFRSF9 protein is biasedly expressed in lymph node, appendix and other tissues. Among its related pathways are TNF Superfamily - Human Ligand-Receptor Interactions and their Associated Functions and Akt Signaling. TNFRSF9 is related to cytokine binding. CD27 is an important paralog of TNFRSF9 gene. TNFRSF9 is associated with some diseases, including Retroperitoneal Hemangiopericytoma and Nodular Goiter.

CD137 Protein (16)

    CD137 Antibody (10)

      CD137 cDNA Clone (69)

      NM_001561.4
      NM_001077508.1
      NM_001077509.1

      In expression vector

      J04492.1

      In expression vector

      NM_001025773.1
      NM_001266128.1
      XM_845243.1
      XM_008265973.2

      In expression vector

      CD137 Lysate (11)

        CD137 Background

        CD137 (also known as 4-1BB) is a surface co-stimulatory glycoprotein originally described as present on activated T lymphocytes, which belongs to the tumor necrosis factor (TNF) receptor superfamily. It is expressed mainly on activated CD4+ and CD8+ T cells, and binds to a high-affinity ligand (4-1BBL) expressed on several antigen-presenting cells such as macrophages and activated B cells. Upon ligand binding, 4-1BB is associated with the tumor necrosis factor receptor–associated factors (TRAFs), the adaptor protein which mediates downstream signaling events including the activation of NF-kappaB and cytokine production. 4-1BB signaling either by binding to 4-1BBL or by antibody ligation delivers signals for T-cell activation and growth, as well as monocyte proliferation and B-cell survival, and plays an important role in the amplification of T cell-mediated immune responses. In addition, CD137 and CD137L are expressed in different human primary tumor tissues, suggesting that they may influence the progression of tumors. Crosslinking of CD137 on activated T cells has shown promise in enhancing anti-tumor immune responses in murine models, and agonistic anti-CD137 antibodies are currently being tested in phase I clinical trials. Soluble forms of CD137 (sCD137) are generated by differential splicing. sCD137 can bind to CD137 ligand to antagonize the costimulatory activities of the membrane-bound CD137 and reduce T cell proliferation and IL-2 secretion.

        CD137 References

        • Sica G, et al. (1999) Biochemical and immunological characteristics of 4-1BB (CD137) receptor and ligand and potential applications in cancer therapy. Arch Immunol Ther Exp (Warsz). 47(5): 275-9.
        • Nam KO, et al. (2005) The therapeutic potential of 4-1BB (CD137) in cancer. Curr Cancer Drug Targets. 5(5): 357-63.
        • Wang Q, et al. (2008) Analysis of CD137 and CD137L expression in human primary tumor tissues. Croat Med J. 49(2): 192-200.
        • Melero I, et al. (2008) Multi-layered action mechanisms of CD137 (4-1BB)-targeted immunotherapies. Trends Pharmacol Sci. 29(8): 383-90.
        • Thum E, et al. (2009) CD137, implications in immunity and potential for therapy. Front Biosci. 14: 4173-88.

        Note: Flag® is a registered trademark of Sigma Aldrich Biotechnology LP. It is used here for informational purposes only.